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Douglas A. Stewart,1 Clayton Smith,2 Ron MacFarland,3 Gary Calandra3Phase I pharmacokinetic (PK) and pharmacodynamic (PD) studies in healthy volunteers demonstrated that
plerixafor (AMD3100), a CXCR4 antagonist, administered either alone or with granulocyte colony-stimulat-
ing factor (G-CSF), resulted in dose-dependent mobilization of CD341 cells in the peripheral blood. The
purpose of this study was to evaluate the safety and the PK and PD of plerixafor with G-CSF in patients
with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). This was a phase II, open-label, single-
arm study conducted in 2 centers in Canada. Patients aged 18 to 70 years with NHL or MM eligible for au-
tologous transplantation were eligible. A total of 22 patients (8 with NHL and 14 with MM) were enrolled in
the study. The patients were given G-CSF (10 mg/kg/day subcutaneously [s.c.]) for 4 days in the morning and
plerixafor 240 mg/kg s.c. on the evening before each day of apheresis. Apheresis was initiated 10 to 11 hours
after each evening dose of plerixafor and after the morning dose of G-CSF. This regimen was repeated for up
to 5 days or until$ 5 106 CD341 cells/kg were collected. The objectives were to determine the safety and
efficacy of plerixafor in patients with NHL andMM, and the PK and PD of a single 240-mg/kg dose of plerixafor
administered after 4 days of G–CSF mobilization in these patients. The median absolute peripheral blood
CD341 cell count increased from 24.0 cells/mL before plerixafor administration to 75.0 cells/mL before
the first apheresis (10 to 11 hours after treatment with plerixafor). The median number of CD341 cells col-
lected in a median of 1 day was 5.7  106 cells/kg in the patients with NHL and 12.0  106 cells/kg in those
with MM. All patients underwent transplantation with prompt and durable engraftment. The PK profile of
plerixafor was characterized in 13 patients (5 with NHL and 8 with MM). Overall, the PK parameters
were comparable in the patients with NHL and those with MM. Plerixafor was rapidly absorbed after s.c.
administration with no observable lag time, with peak plasma concentrations occurring 0.5 hour after admin-
istration in most patients. Plerixafor was rapidly cleared, with a median terminal half-life of 4.6 hours. The
median maximum increase in the number of circulating cells from baseline was 4.2–fold (range, 3.0- to
5.5-fold), with the maximum fold increase occurring approximately 10 hours after plerixafor injection for
all patients. The plerixafor PK and PD profiles in the study patients were consistent with those in healthy
volunteers and support the current dosing regimen and timing of apheresis. Plerixafor was safe and effective
in mobilizing CD341 cells for transplantation.
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6/j.bbmt.2008.10.018stromal cell–derived factor 1a binding to its cognate
receptor CXC chemokine receptor 4 (CXCR4). In
healthy volunteers, plerixafor given as a subcutaneous
(s.c.) injection alone at a dose of 80 mg/kg has been
shown to increase peripheral blood CD341 cells by
3- to 6-fold [1]. CD341 cells were mobilized shortly
after administration and reached maximum levels in
the peripheral blood by 9 hours. In the dose-escalating
portion of this study, plerixafor administered alone
demonstrated linear pharmacokinetics (PK) from 40
to 240 ug/kg. At the 240-mg/kg dose, the peripheral
blood CD341 cell count increased by 10-fold at
9 hours after administration [1].
Hubel et al. [2] examined the PK and pharmacody-
namics (PD) of plerixafor administered alone in a dose-39
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the previous study, plerixafor in combination with
granulocyte colony stimulating factor (G-CSF) re-
sulted in dose-dependent mobilization of CD341 cells
in the peripheral blood and dose-proportional PK.
When a single dose of plerixafor (160 mg/kg s.c.)
was given with G-CSF to healthy volunteers, the num-
ber of peripheral blood CD341 cells increased by 3.8-
fold [3]. The addition of plerixafor on the final day of
the conventional 5-day course of G-CSF treatment re-
sulted in an absolute increase in CD341 cells in the
leukopheresis product from 3.86  106 CD341 cells/
kg after 4 days of G-CSF to 6.02  106 CD341
cells/kg 10 hours after plerixafor administration. It
also was noted that the peak effect was more prolonged
compared with that of plerixafor alone, occurring 10 to
14 hours after administration. Although this study ex-
amined the PD of plerixafor when given with G-CSF,
it did not investigate the PK of plerixafor when given
with G-CSF [3]. In a Phase 2 study in patients with
non-Hodgkin lymphoma (NHL) and multiple mye-
loma (MM), the addition of plerixafor to G-CSF was
well tolerated and increased the likelihood of obtain-
ing $ 5  106 CD341 cells/kg in fewer apheresis ses-
sions compared with G-CSF alone [4].
The PK profile of plerixafor when given with
G-CSF has not yet been evaluated in patients with he-
matologic diseases or in healthy volunteers [3,4]. The
purpose of the present study was to evaluate the safety
and efficacy of plerixafor in patients with NHL and
MM and to examine the PK profile of plerixafor
when given with G-CSF in these patients.METHODS
Study Design
This open-labeled, single-arm study was con-
ducted in 2 Canadian centers to evaluate the safety, ef-
ficacy, and PK and PD of plerixafor. The study was
conducted in compliance with the Declaration of Hel-
sinki and Good Clinical Practice Guidelines. All pa-
tients provided written informed consent to
participate and could withdraw from the study at any
time. The study is registered on www.ClinTrials.gov
(Clinical Trials registration number NCT00396266).
The objectives of the study were (1) to determine
whether plerixafor was generally safe, (2) to evaluate
whether patients with NHL and MM mobilized with
G-CSF and plerixafor had a$ 2–fold increase in circu-
lating CD341 cells from time 0 to 11 hours after a dose
of plerixafor, (3) to determine whether NHL and MM
patients who were mobilized with G-CSF plus plerix-
afor and underwent transplantation with $ 5  106
cells/kg had polymorphonuclear leukocyte (PMN) en-
graftment by day 12 but no later than day 21, and (4) to
examine the PK and PD of a single dose of 240 mg/kgplerixafor administered after 4 days of G–CSF mobili-
zation in patients with NHL or MM.
Eligibility
Patients aged 18 to 70 years with NHL or MM el-
igible for autologous transplantation were screened for
entry into the study. The criteria for inclusion were (1)
no more than 3 previous regimens of chemotherapy,
(2) . 4 weeks since the last cycle of chemotherapy,
(3) Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, (4) recovery from all acute toxic
effects of previous chemotherapy, (5) white blood cell
count . 3.0  109/L, (6) absolute neutrophil count
(ANC) . 1.5  109/L, (7) platelet count . 100 
109/L, (8) serum creatinine # 2.2 mg/dL, (9) liver
function tests\ 2  upper limit of normal, (10) left
ventricular ejection fraction (LVEF). 45% by normal
echocardiogram or multigated angiogram scan, (11)
normal pulmonary function tests, (12) negative for hu-
man immunodeficiency virus, and (13) signed in-
formed consent. The exclusion criteria were (1)
a comorbid condition putting the patient at high risk
for treatment complications, (2) failed previous hema-
topoietic progenitor cell collection, (3) a residual acute
medical condition resulting from previous chemother-
apy, (4) brain metastases or carcinomatous meningitis,
(5) acute infection, (6) fever (. 38BC), (7) positive
pregnancy test, (8) lactation, (9) unwillingness to im-
plement adequate birth control, (10) actual body
weight exceeding 150% of ideal body weight, (11) his-
tory of ventricular arrhythmias, (12) history of at least
grade 2 paresthesias, and (13) previous experimental
therapy within 4 weeks of study enrollment or current
participation in another experimental protocol during
the mobilization phase.
Study Treatment
Patients were first given a mobilizing regimen of
G-CSF (10 mg/kg/day s.c.) for 4 days in the morning,
then plerixafor 240 mg/kg s.c. on the evening before
each day of apheresis. Apheresis was initiated 10 to
11 hours after each evening dose of plerixafor and after
the morning dose of G-CSF. This regimen of G-CSF
10 mg/kg/day s.c. in the morning and plerixafor 240
mg/kg/day s.c. in the evening, followed by apheresis
in the morning, was repeated for up to 5 consecutive
days or until$ 5 106 CD341 cells/kg were collected.
At the investigator’s discretion, $ 5  106 CD341
cells/kg could be collected from patients scheduled
for tandem transplantations if this target could be
reached within 5 days of apheresis.
The patients underwent ablative chemotherapy
and transplantation per institutional standards. All
patients were followed up for the first 30 days and at
3 and 6 months post transplantation. In addition,
complete blood count and differential analyses were
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to assess safety and graft durability.
Safety and Efficacy Assessments
Safety was monitored by clinical and laboratory
evaluations. Adverse events were evaluated through-
out the study period. Hematopoietic progenitor cell
mobilization efficacy was assessed by the change in
peripheral blood CD341 cell count from just before
plerixafor administration to just before apheresis and
by CD341 cell yield in the apheresis product. Fluores-
cent activated cell sorting (FACS) analysis was used to
count CD341 cells in the peripheral blood samples
and apheresis product by both local and central labora-
tories. The time to PMN and platelet engraftment,
along with graft durability up to 12 months posttrans-
plantation, were evaluated. PMN engraftment was de-
fined as the first day of 3 consecutive days of an
absolute PMN count of $ 0.5  109/L, and platelet
engraftment was defined as the first day of a platelet
count of $ 20  109/L without transfusion for 7
days. Graft durability was defined as maintenance of
normal and clinically acceptable blood counts at 3, 6,
and 12 months posttransplantation.
Pharmacokinetic and Pharmacodynamic
Assessments
PK analysis was performed in a subset of patients
who consented to participate in the PK portion of
the study. The PK analysis was planned for aminimum
of 6 patients and a maximum of 8 patients and was to
include 3 or 4 MM patients and 3 or 4 NHL patients.
For the patients included in the PK analyses, blood
samples for the determination of plasma plerixafor
concentrations were collected immediately before dos-
ing and at 0.25, 0.5, 1, 2, 4, 6, and 8 hours after admin-
istration and just before apheresis.
At each time point of PK sample collection, up to
10 mL of blood was collected and immediately put
on ice. Within 30 minutes of collection, the sample
was centrifuged at 3000 rpm for 10 minutes in a refrig-
erated centrifuge that had been precooled to 4C.
Plasma from each sample was transferred to polypro-
pylene tubes in 2 approximately equal aliquots and im-
mediately stored at 270C. One complete set of
samples was shipped to Eurofins AvTech Laboratories
(Kalamazoo, MI). The other set of samples was stored
at 270C pending completion of the analysis of the
original, shipped samples. Plasma samples were ana-
lyzed for plerixafor in accordance with the Food and
Drug Administration guidelines on validating bioana-
lytical methods. All samples were frozen and stored
at 270C on receipt. The samples were analyzed by
liquid chromatography with tandem mass spectral de-
tection. The linear range of the assay was 5.0 to 1000
ng/mL and included 8 calibrators. The precision ofthe quality control samples (12.5, 75, and 750 ng/
mL) was # 7.0%, with a bias of 6 4.0%. At the lower
limit of quantification, the precision was\ 1%, and
the bias was 0.
Plerixafor PK parameters were determined using
noncompartmental methods using exact times of
blood collection [5]. All parameters were calculated us-
ing WinNonlin Professional, version 5.0 (Pharsight
Corp, Mountain View, CA) and SAS for Windows
(SAS Institute, Cary, NC).
The area under the curve from time 0 to the last
observed concentration (AUC0-last) was calculated us-
ing the linear trapezoidal rule. The area under the
curve from time 0 to infinity (AUC0-inf) was calculated
for day 1 using the sum of AUC0-last plus an extrapola-
tion term equal to the last observed concentration di-
vided by the terminal elimination rate constant, l.
The percentage of extrapolated area was calculated as
the ratio of extrapolated area to AUC0–inf, expressed
as a percentage. The area under the curve from time
0 to 10 hours postdose (AUC0-10) was calculated using
the log-linear trapezoidal rule. Apparent clearance was
calculated using dose divided by AUC0-inf. The maxi-
mal observed plasma concentration (Cmax) and time
to maximal observed plasma concentration (Tmax)
were determined from direct observation of the data.
The terminal elimination rate constant l was based
on 3 or more data points, using linear regression of
the log-transformed concentrations against time dur-
ing the elimination phase of the concentration-time
profile. Terminal half-life was calculated on day 1 us-
ing Ln(2)/l. The apparent volume of distribution dur-
ing the terminal elimination phase was calculated as
apparent clearance divided by the terminal elimination
rate constant.
For patients included in the PD analyses, blood
samples for CD341 FACS analysis were collected be-
fore administration and at 1, 2, 4, 6, and 8 after admin-
istration and just before apheresis. Two samples were
collected at each time point. All samples were analyzed
for absolute CD341 count and percentage of CD341
cells in the total sample. FACS analyses were per-
formed by local and central laboratories. In brief,
CD45-FITC (J33) and CD34-PE (581) antibodies
(Beckman-Coulter, Hialeah, FL) were added to 100
uL of peripheral blood/bone marrow or 10 uL of
apheresis product, using a reverse-pipetting technique
to ensure accuracy. Samples were incubated for 10
minutes at room temperature in the dark. Peripheral
blood and bone marrow samples were then lysed using
2 mL of ammonium chloride lysis buffer. In lieu of lys-
ing, 1.0 mL of phosphate-buffered saline was added to
the apheresis products, and 100 uL of Flow Count
beads (Beckman-Coulter) was added to each tube us-
ing the same pipet and technique as before. Flow
cytometry analysis was performed with a Beckman-
Coulter FC500 flow cytometer using a modified
Table 1. Patient Demographics, Baseline Characteristics,
and Medical, Surgical, and Oncology History
NHL (n 5 8) MM (n 5 14)
All Patients
(n 5 22)
Age, years
Mean (SD) 57.9 (8.7) 57.5 (10.3) 57.6 (9.5)
Median 58.0 58.0 58.0
Range 43.0- 67.0 33.0-72.0 33.0-72.0
Sex, n (%)
Male 5 (62.5) 10 (71.4) 15 ( 68.2)
Female 3 (37.5) 4 ( 28.6) 7 ( 31.8)
Ethnicity, n (%)
Caucasian 8 (100.0) 13 (92.9) 21 ( 95.5)
Asian 0 1 (7.1) 1 ( 4.5)
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collected for analysis: forward scatter (FS), log side
scatter (LSS), log fluorescence 1 (LFL1), and LFL2.
Acquisition was halted at 100,000 CD451 events. He-
matopoietic progenitor cells were identified and plot-
ted in 2 histograms (CD45 vs CD34 and FS vs LSS)
using ISHAGE gating criteria: dim CD451, bright
CD341, and forming a discrete cell cluster with
a greater FS signal than that of lymphocytes. The use
of a known amount of Flow Count beads allowed the
determination of absolute CD34 count directly from
the flow cytometer.Weight, kg
Mean (SD) 85.3 (16.3) 86.9 (18.0) 86.3 (17.0)
Median 78.3 84.5 81.5
Range 68.2-111.6 60.3-118.1 60.3-118.1
Disease stage
I-NHL 0 NA NA
II-NHL 1 (12.5) NA NA
III-NHL 1 (12.5) NA NA
IV-NHL 6 (75.0) NA NA
I-MM* NA 4 (28.6) NA
II-MM NA 5 (35.7) NA
III-MM NA 5 (35.7) NA
Time since confirmed diagnosis, months
Mean (SD) 35.8 (40.0) 8.4 (6.4) 18.3 (27.2)
Median 20.0 5.5 6.0
Range 3.0-112.0 2.0-19.0 2.0-112.0
Previous chemotherapy, n (%)
Yes 8 (100.0) 14 (100.0) 22 (100.0)
No 0 0 0
Previous cytotoxic chemotherapy, n (%)
Yes 8 (100.0) 9 (64.3%) 17 (77.3%)
No 0 5 (35.7%) 5 (22.7%)
Previous radiation therapy, n (%)
Yes 0 3 (21.4) 3 (13.6)
No 8 (100.0) 11 (78.6) 19 (86.4)
NHL indicates non-hodgkin lymphoma; MM, multiple myeloma; NA, not
applicable.
*The Durie-Salmon staging system was used.Sample Size and Statistical Analysis
Because this study was designed to provide infor-
mation to use in planning future clinical studies of
plerixafor, there was no specific sample size require-
ment. Some sample size considerations were included,
however. With a total of 20 patients, the 95% confi-
dence interval (CI) for the mean fold increase in the
number of peripheral blood CD341 cells would have
a width of 6 65.7% of the standard deviation of the
change from baseline results, and with a total of 10 pa-
tients, the 95% CI for the mean fold increase in the
number of peripheral blood CD341 cells would have
a width of 6 93.0% of the standard deviation of the
change from baseline results. Therefore, the target pa-
tient enrollment was up to 25 patients.
Categorical data were summarized by disease
group and overall, using frequency tables and present-
ing the patient counts and the percent of patients fall-
ing into each category. Continuous data were
presented in terms of mean, standard deviation, me-
dian, and range by disease group and overall. The
number of days of apheresis needed to reach the target
of . 5  106 CD341 cells/kg was summarized using
Kaplan-Meier methods. SAS software (SAS Institute)
was used to perform all analyses.RESULTS
Patient Characteristics
A total of 22 patients (8 with NHL and 14 with
MM) were enrolled in the study. Patient demographics
and baseline disease characteristics are summarized in
Table 1. The median age in this patient cohort was 58
years. All patients but 1 were Caucasian (95.5%). At
baseline, most of the NHL patients had stage IV dis-
ease, whereas the MM patients were fairly equally dis-
tributed among stage I, stage II, and stage III disease.
All NHL patients received 6 cycles of cytotoxic che-
motherapy consisting of vincristine, doxorubicin, and
cyclophosphamide (Cy). None of the patients received
fludrarabine (Flu) before mobilization. Nine of the
MM patients were treated with cytotoxic chemother-apy comprising vincristine, doxorubicin, and C. One
of these 9 patients also received lenalidomide. The
remaining 5 MM patients received dexamethasone
alone as previous therapy.
Efficacy
Themedian absolute peripheral blood CD341 cell
count increased from 24.0 cells/mL before plerixafor
administration to 75.0 cells/mL before the first apher-
esis (10 to 11 hours after plerixafor administration).
Peripheral blood CD341 cell counts increased from
16.6 to 52.1 cells/mL in the NHL patients and from
30.0 to 86.9 cells/mL in the MM patients (Table 2).
All patients met the endpoint of a$ 2-fold increase
after plerixafor administration. Peripheral blood
CD341 cell count increased by a median of 2.9-fold
10 to 11 hours after the first 240-mg/kg dose of plerix-
afor. The median increase was 2.7-fold in the NHL
patients and 3.1-fold in the MM patients (Table 2).
The median number of CD341 cells collected was
9.2  106 cells/kg overall (5.7  106 cells/kg in the
NHL patients and 12.0  106 cells/kg in the MM
Table 2. Summary of Peripheral BloodCD34+ Cell Count Before andAfter First Plerixafor AdministrationUsing Local Laboratory
Data
NHL (n 5 8) MM (n 5 14) All Patients (n 5 22)
Number of patients (%) 8 (100.0) 13 (92.8)a 21 (95.5)a
Peripheral blood CD34+ count (cells/mL) before the first plerixafor administration
Mean ± SD 25.5 ± 24.6 42.6 ± 33.1 36.1 ± 30.7
Median 16.6 30.0 24.0
Range 6.0-83.0 6.1-108.3 6.0-108.3
Peripheral blood CD34+ count (cells/mL) before apheresis after the first plerixafor administration
Mean ± SD 67.0 ± 52.8 125.3 ± 73.9 103.1 ± 71.4
Median 52.1 86.9 75.0
Range 17.0-182.0 45.8-242.0 17.0-242.0
Fold increase in CD34+ count from before plerixafor to preapheresis for the first plerixafor administration
Mean (SD) 2.8 ± 0.5 3.5 ± 1.5 3.3 ± 1.3
Median 2.7 3.1 2.9
Range 2.2-3.7 2.0-7.6 2.0-7.6
aNHL indicates non-hodgkin lymphoma; MM, multiple myeloma; Laboratory data are not available for 1 patient; thus, that patient is not included in this
analysis.
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CD341 cell collection of $ 2  106 cells/kg for trans-
plantation after amedian of 1.0 day of apheresis (range,
1 to 5 days). Seven of the 8 NHL patients and all 14 of
the MM patients collected $ 2  106 CD341 cells/kg
after a single apheresis session. The remaining NHL
patient collected 2.75  106 CD341 cells/kg after
5 days of apheresis.
Most of the patients (20/22 overall, 6/8 NHL pa-
tients, and 14/14 MM patients) met the optimal target
CD341 cell collection of $ 5 x 106 cells/kg. For the
20 patients who met the optimal target, the median
number of days of apheresis needed to reach the target
was 1.0 day. Four of the 8 NHL patients and 10 of the
14 MM patients collected $ 5  106 CD341 cells/kg
after a single apheresis session. Of the 2 patients who
did not meet the optimal target, 1 patient collected
4.52  106 and 2.75  106 CD341 cells after 3 and
5 days of apheresis, respectively.
All of the patients underwent transplantation. One
patient underwent tandem transplantation. Of the 23
transplantations in this study, none of the patients re-
ceived\2.0 106 CD341 cells/kg, 2 patients received
between 2.0 and 3.5 106 CD341 cells/kg, 8 patients
received between 3.5 and 5.0  106 CD341 cells/kg,
and 13 patients received .5  106 CD341 cells/kg.
Successful PMN engraftment was observed in all
patients. Themedian number of days to PMN engraft-
ment was 11.0 days in the entire cohort, 11.0 days in
the NHL patients, and 12.0 days in the MM patients.
Even though some patients received transplants\5
106 CD341 cells/kg, PMN engraftment occurred by
day 12 in most cases (17/23 transplantation in the en-
tire cohort, 7/8 in the NHL patients, and 10/15 in the
MM patients). PMN engraftment occurred no later
than day 20 in any patient; the maximum time to
PMN engraftment was 14.0 days in the NHL patients
and 20.0 days in the MM patients. Durability was as-
sessed in all patients, and no graft failures were re-
ported.All patients had successful platelet engraftment.
The median time to platelet engraftment was 18.0
days in the entire cohort, 19.0 days in the NHL pa-
tients, and 18.0 days in the MM patients. Platelet en-
graftment occurred by day 21 in most cases (19/23
transplantations in the entire cohort, 6/8 in the
NHL patients, and 13/15 in the MM patients). The
maximum time to platelet engraftment was 24.0 days
in theNHL patients and 23.0 days in theMMpatients.Pharmacokinetic and Pharmacodynamics
The PK profile of plerixafor was characterized in
13 patients (5 NHL and 8 MM). Table 3 summarizes
the PK parameters calculated using noncompartmen-
tal methods, and Figure 1 shows mean plerixafor
plasma concentrations over time on linear and semi-
logarithmic scales. Plerixafor was absorbed rapidly
after s.c. administration with no observable lag time,
with peak plasma concentrations occurring at 0.5
hour after administration in most patients. Plerixafor
had a small apparent volume of distribution, with ame-
dian value of 28.6 L. The drug was cleared rapidly,
with a median terminal half-life of 4.6 hours.
Comparing the PK parameters in the NHL and
MM patients (Table 3) shows that the systemic expo-
sure to plerixafor was slightly higher in the MM
patients. But the differences in the parameters of expo-
sure (Cmax and AUC) and mean plasma concentrations
between the 2 groups are within the expected variabil-
ity of the PK of plerixafor and are not considered clin-
ically relevant. The median terminal half-life was 4.7
hours in the MM patients and 4.5 hours in the NHL
patients.
Along with analyzing peripheral blood CD341
count before each plerixafor administration and before
each apheresis in all patients, we also evaluated CD341
cell counts at multiple time points after the first dose of
plerixafor in a subset of 4 patients with analyzable data
(data not shown). Themedianmaximum increase from
Table 3. Noncompartmental Pharmacokinetic Parameters of Plerixafor
Parameter NHL (n 5 5) MM (n 5 8) All (n 5 13)
Cmax, ng/mL
Mean ± SD 761 ± 101 1029 ± 242 926 ± 237
Median (range) 799 (585-831) 995 (743-1510) 838 (585-1510)
CV 25.6%
Tmax, hours
Mean ± SD 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2
Median (range) 0.5 (0.5-1.0) 0.5 (0.3-1.0) 0.5 (0.3-1.0)
CV 42.2%
AUC0-10, hr*ng/mL
Mean ± SD 3034 ± 412 3945 ± 610 3594 ± 697
Median (range) 3012 (2502-3485) 3866 (3424-5287) 3485 (2502-5287)
CV 19.4%
AUC0-24, hr*ng/mL
Mean ± SD 3686 ± 625 5009 ± 737 4500 ± 946
Median (range) 3907 (2678-4280) 4976 (4180-6516) 4299 (2678-6516)
CV 21.0%
AUC0-inf,hr*ng/mL
Mean ± SD 3768 ± 655 5260 ± 986 4741 ± 1122
Median (range) 4080 (2689-4348) 5051 (4022-6814) 4417 (2681-6770)
CV 23.7%
T1/2, hours
Mean ± SD 4.4 ± 1.1 5.6 ± 2.6 5.1 ± 2.2
Median (range) 4.5 (2.7-5.4) 4.7 (3.7-11.7) 4.6 (2.7-11.7)
CV 42.7%
Cl/F, mL/hr
Mean ± SD 5537 ± 636 4384 ± 1085 4767 ± 1063
Median (range) 5519 (4901-6370) 4195 (2934-5633) 4884 (2954-6360)
CV 22%
Vz/F, mL
Mean ± SD 34,787 ± 10,242 33,534 ± 11,115 33,668 ± 10,531
Median (range) 35484 (23,316-49,808) 29,038 (22,612-52,329) 28,550 (22,203-52,191)
CV 31%
NHL indicates non-hodgkin lymphoma; MM, multiple myeloma; AUC, area under the curve; CV, coefficient of variation.
44 Biol Blood Marrow Transplant 15:39-46, 2009D. A. Stewart et al.baseline in the number of circulating cells was 4.2–fold
(range, 3.0- to 5.5-fold), with the maximum fold in-
crease occurring approximately 10 hours after plerixa-
for injection for all patients.Safety
All patients reported at least 1 adverse event. Most
of the adverse events occurred after ablative chemo-
therapy, consistent with the treatments that patients
were receiving and/or their disease state. Adverse
events considered to be possibly, probably, or defi-
nitely related to the study drug were reported in 17/
22 patients (77.3%) during the mobilization/apheresis
period. The most common related adverse events, oc-
curring in . 5% of patients, were injection site ery-
thema (8/22 patients; 36.4%), injection site pain (4/
22 patients; 18.2%), upper abdominal pain (2/22 pa-
tients; 9.1%), diarrhea (2/22 patients; 9.1%), and
headache (2/22 patients; 9.1%). None of the related
adverse events was classified as severe. All of these ad-
verse events were mild except for 3 moderate events
experienced by 1 patient (injection site reaction, dys-
pepsia, and sensory loss).
Eight of the 22 patients (36.4%) experienced at
least 1 serious adverse event. None of these were con-
sidered related to the study treatment, however. All se-
rious adverse events occurred either before plerixaforadministration or after cytotoxic chemotherapy and
during posttransplantation follow-up. No deaths
were reported.DISCUSSION
Approximately 10% to 30% of the patients failed
to collect the minimum number of hematopoietic pro-
genitor cells ($ 2 106 CD341 cells/kg) using current
mobilization regimens of either G-CSF alone or
G-CSF plus chemotherapy to support high-dose che-
motherapy and autologous hematopoietic progenitor
cell transplantation [8-11]. Most of these patients had
multiple risk factors that put them at high risk for fail-
ure of mobilization [8-11]. Although adding chemo-
therapy to G-CSF generally results in an increase in
CD341 cell collection compared with G-CSF alone,
this addition is associated with significant toxicities
[12-15]. The optimal time to initiate apheresis after
chemotherapy is often unpredictable, and determining
it requires frequent monitoring of white blood cell
count and/or peripheral blood CD341 cell count.
Our findings are consistent with previous reports
indicating that plerixafor is a safe and effective mobili-
zation agent [4,16]. After a single 240-mg/kg dose of
plerixafor administered after 4 days of G-CSF therapy,
peripheral blood CD341 count increased significantly.
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Figure 1. Mean plerixafor plasma concentrations on linear (A) and log-
arithmic (B) scales as a function of time.
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count increased from 24.0 cells/mL from just before
plerixafor administration to 75.0 cells/mL just before
apheresis on the first treatment day. Treatment with
plerixafor resulted in a median 2.9-fold increase in pe-
ripheral bloodCD341 cell count from just before pler-
ixafor administration to just before apheresis on the
first treatment day. All patients demonstrated a $
2-fold increase in peripheral blood CD341 cells dur-
ing this time period. The magnitude of the increase
in peripheral blood CD341 cell count was similar in
the NHL and MM patients. Our findings are consis-
tent with those reported in healthy volunteer studies
and in patients with malignancies [3,4].
Interestingly, we also observed that after 4 days of
G-CSF therapy and before the first dose of plerixafor,
2 patients had a peripheral blood CD341 cell count\
10 cells/mL (a surrogate maker for mobilization fail-
ure), but both of these patients collected $ 2  106
CD341 cells/kg after plerixafor administration. This
finding suggests that using plerixafor as a first-line
therapy may minimize mobilization failure.
The generally accepted minimum number of cells
for transplantation is 2  106 CD341 cells/kg, and the
preferred number is generally$ 5 106 CD341 cells/kg [17]. In this study, the median number of CD341
cells collected was 9.2  106 cells/kg, with all patients
collecting the minimum target of 2  106 cells/kg
CD341 cell, and most of them (20/22 overall) collect-
ing the optimal target of $ 5  106 cells/kg CD341
cells. Importantly, the target was reached in a median
of 1.0 day of apheresis. All patients exhibited successful
PMN and platelet engraftment, and all grafts were du-
rable at the last follow-up. Apart from improving mo-
bilization efficiency, plerixafor was generally well
tolerated and safe, and the safety data in this study
are consistent with previous reports [4,16].
The PK parameters obtained in this study indicate
that plerixafor was rapidly absorbed, had a small appar-
ent volume of distribution, and was rapidly cleared,
with a median terminal half-life of 4.6 hours. These
findings are consistent with those found in healthy vol-
unteers in the absence of G-CSF [1,3]. Comparing the
results inMM andNHLpatients shows that the differ-
ences in PK parameters between the 2 patient popula-
tions are within the expected variability of the PK of
plerixafor and are not considered clinically relevant.
Because renal dysfunction is frequently observed in pa-
tients with MM, further investigation of the PK of
plerixafor in MM patients with renal impairment
may be warranted.
The PK and the PD profiles determined in this
study support the current dosing regimen for plerixa-
for and the timing of apheresis. The current dosing
regimen reliably and predictably mobilizes CD341
cells in most patients, thereby eliminating the need
for routine monitoring of peripheral blood CD341
and coordination of weekend apheresis sessions.ACKNOWLEDGMENTS
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